OpenAI is funding the creation of new biological data to train AI models, following a proposal by clinical trial policy analyst Ruxandra Teslo to acquire detailed regulatory filings and manufacturing strategies from failed biotech companies via their bankruptcy proceedings. The effort addresses a shortage of biological data available for medical AI systems.
Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, an
EU-based hosting, git-push deploys, automatic HTTPS, no cold starts. Free tier with a custom domain — perfect for shipping the agent you just read about.